One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Vogel1 , J. Bridgewater2 , J. Edeline3,4 , R. K. Kelley5 , H. J. Klümpen6 , D. Malka7,8 , J. N. Primrose9 , L. Rimassa 10,11 , A. Stenzinger 12 , J. W. Valle 13,14 & M. Ducreux 8,15 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.10.506
Volume 34, Issue 2, February 2023, Pages 127-140
Moving toward individualized target-based therapies in acute myeloid leukemia
A. Bazinet & H. M. Kantarjian *
doi : 10.1016/j.annonc.2022.11.004
Volume 34, Issue 2, February 2023, Pages 141-151
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
S. I. Labidi-Galy 1,2*y, M. Rodrigues 3,4,5y, J. L. Sandoval 1,2 , J. E. Kurtz 5,6 , F. Heitz 7,8,9 , A. M. Mosconi 10,11 , I. Romero12,13 , U. Denison 14,15 , S. Nagao16,17 , I. Vergote18,19 , G. Parma 20,21 , T. J. Nøttrup 22,23 , E. Rouleau 24 , G. Garnier 25,26 , A. El-Balat 9,27,28 , C. Zamagni 29 , C. MartÃn-Lorente13,30 , E. Pujade-Lauraine 5,6 , A. Fiévet 24 & I. L. Ray-Coquard
doi : 10.1016/j.annonc.2022.11.003
Volume 34, Issue 2, February 2023, Pages 152-162
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial
H. Tang 1,2y, H. Wang 1,2y, Y. Fang 1,2y, J. Y. Zhu2,3y, J. Yin 1,2 , Y. X. Shen 1,2 , Z. C. Zeng2,3 , D. X. Jiang2,4 , Y. Y. Hou2,4 , M. Du 5 , C. H. Lian 6 , Q. Zhao6 , H. J. Jiang 7 , L. Gong 8 , Z. G. Li9 , J. Liu10 , D. Y. Xie11 , W. F. Li12 , C. Chen13 , B. Zheng13 , K. N. Chen 14 , L. Dai 14 , Y. D. Liao 15 , K. Li15 , H. C. Li 16 , N. Q. Zhao17 & L. J. Tan 1
doi : 10.1016/j.annonc.2022.10.508
Volume 34, Issue 2, February 2023, Pages 163-172
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H. Borghaei 1* , T.-E. Ciuleanu 2,3 , J.-S. Lee 4 , A. Pluzanski 5 , R. Bernabe Caro6 , M. Gutierrez 7 , Y. Ohe8 , M. Nishio 9 , J. Goldman10 , N. Ready 11 , D. R. Spigel12 , S. S. Ramalingam 13 , L. G. Paz-Ares 14 , J. F. Gainor 15 , S. Ahmed16 , M. Reck17 , M. Maio 18 , K. J. O’Byrne 19 , A. Memaj 20 , F. Nathan 21 , P. Tran22 , M. D. Hellmann23yz & J. R. Brahmer
doi : 10.1016/j.annonc.2022.11.006
Volume 34, Issue 2, February 2023, Pages 173-185
Molecular and clinical diversity in primary central nervous system lymphoma
I. Hernández-Verdin 1 , E. Kirasic 1 , K. Wienand2,3,4 , K. Mokhtari 1,5 , S. Eimer 6 , H. Loiseau 7,8 , A. Rousseau9,10 , J. Paillassa11 , G. Ahle12 , F. Lerintiu 13 , E. Uro-Coste 14,15,16 , L. Oberic 17 , D. Figarella-Branger 18,19 , O. Chinot 20,21 , G. Gauchotte 22,23,24,25 , L. Taillandier26 , J.-P. Marolleau 27 , M. Polivka28 , C. Adam29 , R. Ursu30 , A. Schmitt31 , N. Barillot 1 , L. Nichelli 32 , F. Lozano-Sánchez 33 , M.-J. Ibañez-Juliá 34 , M. Peyre1,35 , B. Mathon 1,35 , Y. Abada33 , F. Charlotte36 , F. Davi37 , C. Stewart 38 , A. de Reyniès39 , S. Choquet36 , C. Soussain 40 , C. Houillier 33 , B. Chapuy2,3 , K. Hoang-Xuan 1,33 & A. Alentorn
doi : 10.1016/j.annonc.2022.11.002
Volume 34, Issue 2, February 2023, Pages 186-199
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
N. C. Turner 1,2* , C. Swift 3,4 , B. Jenkins5 , L. Kilburn5 , M. Coakley 3,4 , M. Beaney 3 , L. Fox 5 , K. Goddard 5 , I. Garcia-Murillas 3 , P. Proszek6 , P. Hall 7 , C. Harper-Wynne8 , T. Hickish 9 , S. Kernaghan5 , I. R. Macpherson 10 , A. F. C. Okines 2 , C. Palmieri 11 , S. Perry 5 , K. Randle12 , C. Snowdon 5 , H. Stobart 12 , A. M. Wardley13 , D. Wheatley 14 , S. Waters 15 , M. C. Winter 16 , M. Hubank 3,4 , S. D. Allen4 & J. M. Bliss 5 , on behalf of the c-TRAK TN investigators
doi : 10.1016/j.annonc.2022.11.005
Volume 34, Issue 2, February 2023, Pages 200-211
